|
US20080305120A1
(en)
|
2004-06-17 |
2008-12-11 |
Medimmune, Inc. |
Immunogenic Compositions Comprising Hmgb 1 Polypeptides
|
|
DE102004034461B4
(de)
|
2004-07-16 |
2008-02-07 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
ES2291071B1
(es)
|
2005-06-13 |
2009-03-16 |
Proyecto De Biomedicina Cima, S.L. |
Agentes y metodos basados en el uso del dominio eda de la fibronectina.
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
DE09780481T1
(de)
|
2008-07-11 |
2012-01-26 |
Medizinische Universität Innsbruck |
Agonisten von nr2f6 zur immunsuppression
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
DE102008050860A1
(de)
|
2008-10-08 |
2010-04-15 |
Dorothee Von Laer |
LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
ES2655687T3
(es)
|
2009-09-11 |
2018-02-21 |
Proyecto De Biomedicina Cima, S.L. |
Composiciones terapéuticas para el tratamiento de enfermedades causadas por HPV
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
WO2012015979A2
(en)
|
2010-07-27 |
2012-02-02 |
The Regents Of The University Of California |
Hmgb1-derived peptides enhance immune response to antigens
|
|
US9555074B2
(en)
|
2010-10-08 |
2017-01-31 |
Regents Of The University Of Minnesota |
Annexin II compositions
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
SG11201403714TA
(en)
|
2011-12-30 |
2014-07-30 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
|
US9597393B2
(en)
|
2012-02-09 |
2017-03-21 |
Av Therapeutics, Inc. |
Synthetic toll-like receptor-4 (TLR-4) agonist peptides
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
KR20190057345A
(ko)
*
|
2016-09-21 |
2019-05-28 |
아말 테라퓨틱스 에스에이 |
암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
|
|
TW202600150A
(zh)
*
|
2019-01-25 |
2026-01-01 |
德商百靈佳殷格翰國際股份有限公司 |
編碼ccl21之重組棒狀病毒
|